A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients

被引：10
作者：
Gui, Yu [1 ]
Xu, Shuman [1 ]
Yang, Xi [1 ]
Gu, Lu [2 ,3 ]
Zhang, Ze [2 ,3 ]
Luo, Xiangdong [2 ,3 ]
Chen, Li [1 ,3 ]
机构：
[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China
[2] Third Mil Med Univ, Burn Res Inst, Southwest Hosp, Chongqing 400038, Peoples R China
[3] Chongqing Key Lab Dis Prote, Natl Key Lab Trauma & Burns, Chongqing, Peoples R China
来源：
BIOMARKERS IN MEDICINE | 2016年 / 10卷 / 07期
基金：
中国国家自然科学基金;
关键词：
biomarkers; chemotherapy; meta-analysis; prognosis; triple-negative breast cancer; ANTHRACYCLINE-BASED CHEMOTHERAPY; INTERNATIONAL EXPERT CONSENSUS; NEOADJUVANT CHEMOTHERAPY; GROWTH-FACTOR; ADJUVANT CHEMOTHERAPY; CELL-CYCLE; PROMOTER METHYLATION; PRIMARY THERAPY; FALLOPIAN-TUBE; OVARIAN-CANCER;
D O I：
10.2217/bmm-2015-0064
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Identification of biomarkers that has the ability to predict triple negative breast cancer (TNBC) prognosis especially in patients undergoing chemotherapy is very important. Methods: The cohort studies that reported association between chemotherapy biomarker expression and survival outcome in TNBC patients were included in our analysis. Results: The promising markers that emerged for the prediction of disease-free survival and overall survival included Ki67, BRCA1 methylation and LC3B. Furthermore, Ki67 appeared to be also significantly associated with worse disease-free survival in TNBC patients who received anthracycline-based chemotherapy. Conclusion: This meta-analysis demonstrated that in TNBC patients receiving chemotherapy, Ki67 is a predictor for poor prognosis, BRCA1 methylation and LC3B are also potential prognostic markers. In addition, the TNBC patients with high Ki67 expression seems to display resistance to anthracycline-based chemotherapy.
引用
收藏
页码：771 / 790
页数：20
相关论文
共 77 条
[1]   Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings [J].
Abdel-Fatah, T. M. A. ;
Perry, C. ;
Dickinson, P. ;
Ball, G. ;
Moseley, P. ;
Madhusudan, S. ;
Ellis, I. O. ;
Chan, S. Y. T. .
ANNALS OF ONCOLOGY, 2013, 24 (11) :2801-2807
[2]   Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience [J].
Asleh-Aburaya, Karama ;
Fried, Georgeta .
SPRINGERPLUS, 2015, 4 :1-7
[3]  
Ataseven B, 2013, ANTICANCER RES, V33, P3759
[4]   A genetic epidemiological study of carcinoma of the fallopian tube [J].
Aziz, S ;
Kuperstein, G ;
Rosen, B ;
Cole, D ;
Nedelcu, R ;
McLaughlin, J ;
Narod, SA .
GYNECOLOGIC ONCOLOGY, 2001, 80 (03) :341-345
[5]   Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations [J].
Bayraktar, Soley ;
Gutierrez-Barrera, Angelica M. ;
Liu, Diane ;
Tasbas, Tunc ;
Akar, Ugur ;
Litton, Jennifer K. ;
Lin, E. ;
Albarracin, Constance T. ;
Meric-Bernstam, Funda ;
Gonzalez-Angulo, Ana M. ;
Hortobagyi, Gabriel N. ;
Arun, Banu K. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (01) :145-153
[6]   Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review [J].
Bernier, Jacques ;
Poortmans, Philip .
BREAST, 2015, 24 (02) :100-106
[7]   p53 in breast cancer subtypes and new insights into response to chemotherapy [J].
Bertheau, Philippe ;
Lehmann-Che, Jacqueline ;
Varna, Mariana ;
Dumay, Anne ;
Poirot, Brigitte ;
Porcher, Raphael ;
Turpin, Elisabeth ;
Plassa, Louis-Francois ;
de Roquancourt, Anne ;
Bourstyn, Edwige ;
de Cremoux, Patricia ;
Janin, Anne ;
Giacchetti, Sylvie ;
Espie, Marc ;
de The, Hugues .
BREAST, 2013, 22 :S27-S29
[8]  
Billgren AM, 1999, ACTA ONCOL, V38, P597
[9]   P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas [J].
Bogina, Giuseppe S. ;
Lunardi, Gianluigi ;
Marcolini, Lisa ;
Brunelli, Matte ;
Bortesi, Laura ;
Marconi, Marcella ;
Coati, Francesca ;
Valerio, Matteo ;
Guerriero, Massimo ;
Massocco, Alberto ;
Pegoraro, Maria C. ;
Zamboni, Giuseppe .
MODERN PATHOLOGY, 2014, 27 (02) :204-213
[10]  
Brown RW, 1996, CLIN CANCER RES, V2, P585
12345678